-
1
-
-
84867163670
-
Molecular pathogenesis of mantle cell lymphoma
-
Jares P, Colomer D, Campo E. Molecular pathogenesis of mantle cell lymphoma. J Clin Invest. 2012;122(10):3416-3423.
-
(2012)
J Clin Invest.
, vol.122
, Issue.10
, pp. 3416-3423
-
-
Jares, P.1
Colomer, D.2
Campo, E.3
-
2
-
-
84867513141
-
Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features
-
Navarro A, Clot G, Royo C, et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res. 2012;72(20):5307-5316.
-
(2012)
Cancer Res.
, vol.72
, Issue.20
, pp. 5307-5316
-
-
Navarro, A.1
Clot, G.2
Royo, C.3
-
3
-
-
76749118059
-
Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma
-
Fernàndez V, Salamero O, Espinet B, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res. 2010;70(4):1408-1418.
-
(2010)
Cancer Res.
, vol.70
, Issue.4
, pp. 1408-1418
-
-
Fernàndez, V.1
Salamero, O.2
Espinet, B.3
-
4
-
-
84864877555
-
Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease
-
Royo C, Navarro A, Clot G, et al. Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease. Leukemia. 2012;26(8):1895-1898.
-
(2012)
Leukemia
, vol.26
, Issue.8
, pp. 1895-1898
-
-
Royo, C.1
Navarro, A.2
Clot, G.3
-
5
-
-
38349103985
-
-
Ek S, Dictor M, Jerkeman M, Jirström K, Borrebaeck CA. Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma. Blood. 2008;111(2): 800-805.
-
(2008)
Borrebaeck CA. Nuclear Expression of the Non B-cell Lineage Sox11 Transcription Factor Identifies Mantle Cell Lymphoma. Blood
, vol.111
, Issue.2
, pp. 800-805
-
-
Ek, S.1
Dictor, M.2
Jerkeman, M.3
Jirström, K.4
-
6
-
-
70449435195
-
SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype
-
Mozos A, Royo C, Hartmann E, et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica. 2009;94(11):1555-1562.
-
(2009)
Haematologica
, vol.94
, Issue.11
, pp. 1555-1562
-
-
Mozos, A.1
Royo, C.2
Hartmann, E.3
-
7
-
-
84877929950
-
SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma
-
Vegliante MC, Palomero J, Pérez-Galán P, et al. SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. Blood. 2013;121(12):2175-2185.
-
(2013)
Blood
, vol.121
, Issue.12
, pp. 2175-2185
-
-
Vegliante, M.C.1
Palomero, J.2
Pérez-Galán, P.3
-
8
-
-
84874407720
-
CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma
-
Salaverria I, Royo C, Carvajal-Cuenca A, et al. CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma. Blood. 2013;121(8):1394-1402.
-
(2013)
Blood
, vol.121
, Issue.8
, pp. 1394-1402
-
-
Salaverria, I.1
Royo, C.2
Carvajal-Cuenca, A.3
-
9
-
-
33645729415
-
The ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma
-
Katzenberger T, Petzoldt C, Höller S, et al. The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood. 2006;107(8):3407.
-
(2006)
Blood
, vol.107
, Issue.8
, pp. 3407
-
-
Katzenberger, T.1
Petzoldt, C.2
Höller, S.3
-
10
-
-
84887285547
-
Landscape of somatic mutations and clonal evolution in mantle cell lymphoma
-
Beà S, Valdés-Mas R, Navarro A, et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci USA. 2013;110(45):18250-18255.
-
(2013)
Proc Natl Acad Sci USA
, vol.110
, Issue.45
, pp. 18250-18255
-
-
Beà, S.1
Valdés-Mas, R.2
Navarro, A.3
-
11
-
-
84903182870
-
The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells
-
Zhang J, Jima D, Moffitt AB, et al. The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells. Blood. 2014;123(19):2988-2996.
-
(2014)
Blood
, vol.123
, Issue.19
, pp. 2988-2996
-
-
Zhang, J.1
Jima, D.2
Moffitt, A.B.3
-
12
-
-
84857763426
-
Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma
-
Kridel R, Meissner B, Rogic S, et al. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood. 2012;119(9):1963-1971.
-
(2012)
Blood
, vol.119
, Issue.9
, pp. 1963-1971
-
-
Kridel, R.1
Meissner, B.2
Rogic, S.3
-
13
-
-
84891867381
-
Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma
-
Rahal R, Frick M, Romero R, et al. Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma. Nat Med. 2014;20(1):87-92.
-
(2014)
Nat Med.
, vol.20
, Issue.1
, pp. 87-92
-
-
Rahal, R.1
Frick, M.2
Romero, R.3
-
14
-
-
84892395662
-
Unlocking new therapeutic targets and resistance mechanisms in mantle cell lymphoma
-
Colomer D, Campo E. Unlocking new therapeutic targets and resistance mechanisms in mantle cell lymphoma. Cancer Cell. 2014;25(1):7-9.
-
(2014)
Cancer Cell.
, vol.25
, Issue.1
, pp. 7-9
-
-
Colomer, D.1
Campo, E.2
-
15
-
-
78650985963
-
Mantle cell lymphoma: Biology, pathogenesis, and the molecular basis of treatment in the genomic era
-
Pérez-Galán P, Dreyling M, Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood. 2011;117(1):26-38.
-
(2011)
Blood
, vol.117
, Issue.1
, pp. 26-38
-
-
Pérez-Galán, P.1
Dreyling, M.2
Wiestner, A.3
-
16
-
-
84881225049
-
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
-
Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507-516.
-
(2013)
N Engl J Med.
, vol.369
, Issue.6
, pp. 507-516
-
-
Wang, M.L.1
Rule, S.2
Martin, P.3
-
17
-
-
78149266421
-
Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma
-
Baran-Marszak F, Boukhiar M, Harel S, et al. Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma. Haematologica. 2010; 95(11):1865-1872.
-
(2010)
Haematologica.
, vol.95
, Issue.11
, pp. 1865-1872
-
-
Baran-Marszak, F.1
Boukhiar, M.2
Harel, S.3
-
18
-
-
27244452464
-
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine
-
Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005; 23(28):7013-7023.
-
(2005)
J Clin Oncol.
, vol.23
, Issue.28
, pp. 7013-7023
-
-
Romaguera, J.E.1
Fayad, L.2
Rodriguez, M.A.3
-
19
-
-
77954334194
-
Ten-year follow-up after intense chemoimmunotherapy with rituximab-hypercvad alternating with rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma
-
Romaguera JE, Fayad LE, Feng L, et al. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol. 2010;150(2):200-208.
-
(2010)
Br J Haematol.
, vol.150
, Issue.2
, pp. 200-208
-
-
Romaguera, J.E.1
Fayad, L.E.2
Feng, L.3
-
20
-
-
84855796484
-
Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from gruppo italiano studio linfomi
-
Merli F, Luminari S, Ilariucci F, et al. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. Br J Haematol. 2012;156(3):346-353.
-
(2012)
Br J Haematol.
, vol.156
, Issue.3
, pp. 346-353
-
-
Merli, F.1
Luminari, S.2
Ilariucci, F.3
-
21
-
-
84878457954
-
A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213
-
Bernstein SH, Epner E, Unger JM, et al. A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. Ann Oncol. 2013;24(6):1587-1593.
-
(2013)
Ann Oncol.
, vol.24
, Issue.6
, pp. 1587-1593
-
-
Bernstein, S.H.1
Epner, E.2
Unger, J.M.3
-
22
-
-
53449089095
-
Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivopurged stem cell rescue: A nonrandomized phase 2 multicenter study by the nordic lymphoma group
-
Geisler CH, Kolstad A, Laurell A, et al; Nordic Lymphoma Group. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivopurged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008;112(7):2687-2693.
-
(2008)
Blood
, vol.112
, Issue.7
, pp. 2687-2693
-
-
Geisler, C.H.1
Kolstad, A.2
Laurell, A.3
-
23
-
-
84863822702
-
Nordic MCL2 trial update: Six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC 1 autologous stem-cell support: Still very long survival but late relapses do occur
-
Geisler CH, Kolstad A, Laurell A, et al; Nordic Lymphoma Group. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC 1 autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol. 2012;158(3):355-362.
-
(2012)
Br J Haematol.
, vol.158
, Issue.3
, pp. 355-362
-
-
Geisler, C.H.1
Kolstad, A.2
Laurell, A.3
-
24
-
-
84883133544
-
Alternating courses of 3xCHOP and 3xDHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma
-
ASH Annual Meeting Abstracts: Final analysis of the MCL younger trial of the European mantle cell lymphoma network. [abstract]
-
Hermine O, Hoster E, Walewski J, et al. Alternating courses of 3xCHOP and 3xDHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: final analysis of the MCL younger trial of the European Mantle Cell Lymphoma Network. [abstract]. Blood 2012;120(21):151. ASH Annual Meeting Abstracts.
-
(2012)
Blood
, vol.120
, Issue.21
, pp. 151
-
-
Hermine, O.1
Hoster, E.2
Walewski, J.3
-
25
-
-
20144376591
-
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: Results of a prospective randomized trial of the german low grade lymphoma study group (GLSG)
-
Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol. 2005;23(9):1984-1992.
-
(2005)
J Clin Oncol.
, vol.23
, Issue.9
, pp. 1984-1992
-
-
Lenz, G.1
Dreyling, M.2
Hoster, E.3
-
26
-
-
0034845543
-
Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma
-
Cohen BJ, Moskowitz C, Straus D, Noy A, Hedrick E, Zelenetz A. Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma. Leuk Lymphoma. 2001;42(5): 1015-1022.
-
(2001)
Leuk Lymphoma.
, vol.42
, Issue.5
, pp. 1015-1022
-
-
Cohen, B.J.1
Moskowitz, C.2
Straus, D.3
Noy, A.4
Hedrick, E.5
Zelenetz, A.6
-
27
-
-
52649177173
-
Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-hodgkin's lymphoma
-
Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol. 2008;26(27):4473-4479.
-
(2008)
J Clin Oncol.
, vol.26
, Issue.27
, pp. 4473-4479
-
-
Robinson, K.S.1
Williams, M.E.2
Van Der Jagt, R.H.3
-
28
-
-
84864715966
-
Treatment of older patients with mantle-cell lymphoma
-
Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012;367(6):520-531.
-
(2012)
N Engl J Med.
, vol.367
, Issue.6
, pp. 520-531
-
-
Kluin-Nelemans, H.C.1
Hoster, E.2
Hermine, O.3
-
29
-
-
84875840492
-
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An openlabel, multicentre, randomised, phase 3 non-inferiority trial
-
Rummel MJ, Niederle N, Maschmeyer G, et al; Study group indolent Lymphomas (StiL). Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an openlabel, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873): 1203-1210.
-
(2013)
Lancet.
, vol.381
, Issue.9873
, pp. 1203-1210
-
-
Rummel, M.J.1
Niederle, N.2
Maschmeyer, G.3
-
30
-
-
84900423736
-
Open-label, randomized, noninferiority study of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of advanced indolent NHL or MCL: The BRIGHT study
-
Flinn IW, van der Jagt R, Kahl BS, et al. Open-label, randomized, noninferiority study of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of advanced indolent NHL or MCL: the BRIGHT study. Blood. 2014;123(19): 2944-2952.
-
(2014)
Blood
, vol.123
, Issue.19
, pp. 2944-2952
-
-
Flinn, I.W.1
Van Der Jagt, R.2
Kahl, B.S.3
-
31
-
-
0033968522
-
European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma
-
Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol. 2000;18(2):317-324.
-
(2000)
J Clin Oncol.
, vol.18
, Issue.2
, pp. 317-324
-
-
Foran, J.M.1
Rohatiner, A.Z.2
Cunningham, D.3
-
32
-
-
0024401168
-
Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: Anthracycline does not improve the prognosis
-
Meusers P, Engelhard M, Bartels H, et al. Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis. Hematol Oncol. 1989;7(5):365-380.
-
(1989)
Hematol Oncol.
, vol.7
, Issue.5
, pp. 365-380
-
-
Meusers, P.1
Engelhard, M.2
Bartels, H.3
-
33
-
-
79951718283
-
Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: A highly effective regimen
-
Sachanas S, Pangalis GA, Vassilakopoulos TP, et al. Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen. Leuk Lymphoma. 2011;52(3):387-393.
-
(2011)
Leuk Lymphoma.
, vol.52
, Issue.3
, pp. 387-393
-
-
Sachanas, S.1
Pangalis, G.A.2
Vassilakopoulos, T.P.3
-
34
-
-
47249112184
-
Longterm results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the north Central cancer treatment group
-
Inwards DJ, Fishkin PA, Hillman DW, et al. Longterm results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group. Cancer. 2008;113(1):108-116.
-
(2008)
Cancer.
, vol.113
, Issue.1
, pp. 108-116
-
-
Inwards, D.J.1
Fishkin, P.A.2
Hillman, D.W.3
-
35
-
-
4944229959
-
Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma
-
Kaufmann H, Raderer M, Wöhrer S, et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood. 2004;104(8):2269-2271.
-
(2004)
Blood
, vol.104
, Issue.8
, pp. 2269-2271
-
-
Kaufmann, H.1
Raderer, M.2
Wöhrer, S.3
-
36
-
-
77956270210
-
Outcome following reduced-intensity allogeneic stem cell transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): A study of the British society for blood and marrow transplantation
-
Cook G, Smith GM, Kirkland K, et al; Clinical Trials Committee (CTC) of the British Society for Blood and Marrow Transplantation (BSBMT). Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2010;16(10):1419-1427.
-
(2010)
Biol Blood Marrow Transplant
, vol.16
, Issue.10
, pp. 1419-1427
-
-
Cook, G.1
Smith, G.M.2
Kirkland, K.3
-
37
-
-
0642368565
-
Nonablative allogeneic stem-cell transplantation for advanced/ recurrent mantle-cell lymphoma
-
Khouri IF, Lee M-S, Saliba RM, et al. Nonablative allogeneic stem-cell transplantation for advanced/ recurrent mantle-cell lymphoma. J Clin Oncol. 2003;21(23):4407-4412.
-
(2003)
J Clin Oncol.
, vol.21
, Issue.23
, pp. 4407-4412
-
-
Khouri, I.F.1
Lee, M.-S.2
Saliba, R.M.3
-
38
-
-
84920620829
-
Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: A retrospective study of the European group for blood and marrow transplantation (EBMT)
-
Dietrich S, Boumendil A, Finel H, et al. Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol. 2014;25(5): 1053-1058.
-
(2014)
Ann Oncol.
, vol.25
, Issue.5
, pp. 1053-1058
-
-
Dietrich, S.1
Boumendil, A.2
Finel, H.3
-
39
-
-
33748751004
-
Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: A pilot study from the wisconsin oncology network
-
Kahl BS, Longo WL, Eickhoff JC, et al; Wisconsin Oncology Network. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. Ann Oncol. 2006;17(9): 1418-1423.
-
(2006)
Ann Oncol.
, vol.17
, Issue.9
, pp. 1418-1423
-
-
Kahl, B.S.1
Longo, W.L.2
Eickhoff, J.C.3
-
40
-
-
84891442057
-
Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: Results from the phase II GAUGUIN study
-
Morschhauser FA, Cartron G, Thieblemont C, et al. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013;31(23): 2912-2919.
-
(2013)
J Clin Oncol.
, vol.31
, Issue.23
, pp. 2912-2919
-
-
Morschhauser, F.A.1
Cartron, G.2
Thieblemont, C.3
-
41
-
-
84899473410
-
Ofatumumab monotherapy in relapsed/ refractory mantle cell lymphoma - A phase II trial
-
Furtado M, Dyer MJS, Johnson R, Berrow M, Rule S. Ofatumumab monotherapy in relapsed/ refractory mantle cell lymphoma-a phase II trial. Br J Haematol. 2014;165(4):575-578.
-
(2014)
Br J Haematol.
, vol.165
, Issue.4
, pp. 575-578
-
-
Furtado, M.1
Dyer, M.J.S.2
Johnson, R.3
Berrow, M.4
Rule, S.5
-
42
-
-
70449727887
-
Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma
-
Wang M, Oki Y, Pro B, et al. Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009;27(31):5213-5218.
-
(2009)
J Clin Oncol.
, vol.27
, Issue.31
, pp. 5213-5218
-
-
Wang, M.1
Oki, Y.2
Pro, B.3
-
43
-
-
84865765565
-
Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern cooperative oncology group study E1499
-
Smith MR, Li H, Gordon L, et al. Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499. J Clin Oncol. 2012;30(25):3119-3126.
-
(2012)
J Clin Oncol.
, vol.30
, Issue.25
, pp. 3119-3126
-
-
Smith, M.R.1
Li, H.2
Gordon, L.3
-
44
-
-
84900442345
-
Nordic MCL-3 study: Beam/C conditioning intensified with 90Y-ibritumomab-tiuxetan in responding non-CR patients followed by autologous transplant in mantle cell lymphoma
-
Kolstad A, Laurell A, Jerkeman M, et al. Nordic MCL-3 study: BEAM/C conditioning intensified with 90Y-Ibritumomab-Tiuxetan in responding non-CR patients followed by autologous transplant in mantle cell lymphoma. Blood. 2014; 123(19):2953-2959.
-
(2014)
Blood
, vol.123
, Issue.19
, pp. 2953-2959
-
-
Kolstad, A.1
Laurell, A.2
Jerkeman, M.3
-
45
-
-
84884961372
-
First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase pilot trial from the GELTAMO group
-
Arranz R, García-Noblejas A, Grande C, et al. First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase pilot trial from the GELTAMO group. Haematologica. 2013;98(10):1563-1570.
-
(2013)
Haematologica.
, vol.98
, Issue.10
, pp. 1563-1570
-
-
Arranz, R.1
García-Noblejas, A.2
Grande, C.3
-
46
-
-
70349331498
-
Preemptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma
-
Andersen NS, Pedersen LB, Laurell A, et al. Preemptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J Clin Oncol. 2009; 27(26):4365-4370.
-
(2009)
J Clin Oncol.
, vol.27
, Issue.26
, pp. 4365-4370
-
-
Andersen, N.S.1
Pedersen, L.B.2
Laurell, A.3
-
47
-
-
84875606235
-
Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-hodgkin lymphoma ineligible for intensive regimens or autologous transplantation
-
Visco C, Finotto S, Zambello R, et al. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol. 2013;31(11): 1442-1449.
-
(2013)
J Clin Oncol.
, vol.31
, Issue.11
, pp. 1442-1449
-
-
Visco, C.1
Finotto, S.2
Zambello, R.3
-
48
-
-
84865725149
-
Prolonged immunochemotherapy with rituximab, cytarabine and fludarabine added to cyclophosphamide, doxorubicin, vincristine and prednisolone and followed by rituximab maintenance in untreated elderly patients with mantle cell lymphoma: A prospective study by the finnish lymphoma group
-
Räty R, Honkanen T, Jantunen E, et al. Prolonged immunochemotherapy with rituximab, cytarabine and fludarabine added to cyclophosphamide, doxorubicin, vincristine and prednisolone and followed by rituximab maintenance in untreated elderly patients with mantle cell lymphoma: a prospective study by the Finnish Lymphoma Group. Leuk Lymphoma. 2012;53(10):1920-1928.
-
(2012)
Leuk Lymphoma.
, vol.53
, Issue.10
, pp. 1920-1928
-
-
Räty, R.1
Honkanen, T.2
Jantunen, E.3
-
49
-
-
33750625445
-
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
-
Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24(30):4867-4874.
-
(2006)
J Clin Oncol.
, vol.24
, Issue.30
, pp. 4867-4874
-
-
Fisher, R.I.1
Bernstein, S.H.2
Kahl, B.S.3
-
50
-
-
68949102180
-
Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma
-
Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009;27(23):3822-3829.
-
(2009)
J Clin Oncol.
, vol.27
, Issue.23
, pp. 3822-3829
-
-
Hess, G.1
Herbrecht, R.2
Romaguera, J.3
-
51
-
-
84889099537
-
Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: Phase II MCL-001 (EMERGE) study
-
Goy A, Sinha R, Williams ME, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol. 2013;31(29): 3688-3695.
-
(2013)
J Clin Oncol.
, vol.31
, Issue.29
, pp. 3688-3695
-
-
Goy, A.1
Sinha, R.2
Williams, M.E.3
-
52
-
-
79953182631
-
Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: A phase 2 study
-
Ansell SM, Tang H, Kurtin PJ, et al. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncol. 2011;12(4):361-368.
-
(2011)
Lancet Oncol.
, vol.12
, Issue.4
, pp. 361-368
-
-
Ansell, S.M.1
Tang, H.2
Kurtin, P.J.3
-
53
-
-
77956853122
-
Phase I trial of bortezomib in combination with rituximab-hypercvad alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma
-
Romaguera JE, Fayad LE, McLaughlin P, et al. Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma. Br J Haematol. 2010;151(1):47-53.
-
(2010)
Br J Haematol.
, vol.151
, Issue.1
, pp. 47-53
-
-
Romaguera, J.E.1
Fayad, L.E.2
McLaughlin, P.3
-
54
-
-
79952154013
-
Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma
-
Ruan J, Martin P, Furman RR, et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol. 2011;29(6):690-697.
-
(2011)
J Clin Oncol.
, vol.29
, Issue.6
, pp. 690-697
-
-
Ruan, J.1
Martin, P.2
Furman, R.R.3
-
55
-
-
84897521309
-
Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: An eastern cooperative oncology group study (E1405)
-
Chang JE, Li H, Smith MR, et al. Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405). Blood. 2014;123(11):1665-1673.
-
(2014)
Blood
, vol.123
, Issue.11
, pp. 1665-1673
-
-
Chang, J.E.1
Li, H.2
Smith, M.R.3
-
56
-
-
70349300630
-
Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: A randomized phase 2 trial from the french adult lymphoma study group (GELA)
-
Ribrag V, Gisselbrecht C, Haioun C, et al. Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA). Cancer. 2009;115(19):4540-4546.
-
(2009)
Cancer.
, vol.115
, Issue.19
, pp. 4540-4546
-
-
Ribrag, V.1
Gisselbrecht, C.2
Haioun, C.3
-
57
-
-
33847297956
-
Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma
-
Weigert O, Pastore A, Rieken M, Lang N, Hiddemann W, Dreyling M. Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma. Leukemia. 2007;21(3):524-528.
-
(2007)
Leukemia
, vol.21
, Issue.3
, pp. 524-528
-
-
Weigert, O.1
Pastore, A.2
Rieken, M.3
Lang, N.4
Hiddemann, W.5
Dreyling, M.6
-
58
-
-
68549133393
-
A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - Long-term results of a multicenter observation study
-
Weigert O, Weidmann E, Mueck R, et al. A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study. Leuk Lymphoma. 2009;50(5):716-722.
-
(2009)
Leuk Lymphoma.
, vol.50
, Issue.5
, pp. 716-722
-
-
Weigert, O.1
Weidmann, E.2
Mueck, R.3
-
59
-
-
80053567237
-
VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: A wisconsin oncology network study
-
Chang JE, Peterson C, Choi S, et al. VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study. Br J Haematol. 2011; 155(2):190-197.
-
(2011)
Br J Haematol.
, vol.155
, Issue.2
, pp. 190-197
-
-
Chang, J.E.1
Peterson, C.2
Choi, S.3
-
60
-
-
84863107308
-
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: A phase 1/2 clinical trial
-
Wang M, Fayad L, Wagner-Bartak N, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol. 2012;13(7):716-723.
-
(2012)
Lancet Oncol.
, vol.13
, Issue.7
, pp. 716-723
-
-
Wang, M.1
Fayad, L.2
Wagner-Bartak, N.3
-
61
-
-
84866875871
-
Singleagent lenalidomide in relapsed/refractory mantle cell lymphoma: Results from a UK phase II study suggest activity and possible gender differences
-
Eve HE, Carey S, Richardson SJ, et al. Singleagent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences. Br J Haematol. 2012;159(2):154-163.
-
(2012)
Br J Haematol.
, vol.159
, Issue.2
, pp. 154-163
-
-
Eve, H.E.1
Carey, S.2
Richardson, S.J.3
-
62
-
-
84899475041
-
Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: Multicentre, single-arm, phase 2 study
-
Wang M, Popplewell LL, Collins RH Jr, et al. Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study. Br J Haematol. 2014;165(4):510-518.
-
(2014)
Br J Haematol.
, vol.165
, Issue.4
, pp. 510-518
-
-
Wang, M.1
Popplewell, L.L.2
Collins, R.H.3
-
63
-
-
84901724050
-
Results of a phase I study of idelalisib, a PI3Kδ inhibitor, in patients with relapsed or refractory mantle cell lymphoma (MCL)
-
Kahl BS, Spurgeon SE, Furman RR, et al. Results of a phase I study of idelalisib, a PI3Kδ inhibitor, in patients with relapsed or refractory mantle cell lymphoma (MCL). Blood. 2014;123(22): 3398-3405.
-
(2014)
Blood
, vol.123
, Issue.22
, pp. 3398-3405
-
-
Kahl, B.S.1
Spurgeon, S.E.2
Furman, R.R.3
-
64
-
-
84880880724
-
New insights into pre-BCR and BCR signalling with relevance to B cell malignancies
-
Rickert RC. New insights into pre-BCR and BCR signalling with relevance to B cell malignancies. Nat Rev Immunol. 2013;13(8):578-591.
-
(2013)
Nat Rev Immunol.
, vol.13
, Issue.8
, pp. 578-591
-
-
Rickert, R.C.1
-
65
-
-
84871806385
-
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies
-
Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31(1):88-94.
-
(2013)
J Clin Oncol.
, vol.31
, Issue.1
, pp. 88-94
-
-
Advani, R.H.1
Buggy, J.J.2
Sharman, J.P.3
-
66
-
-
84896732823
-
Bruton's tyrosine kinase (BTK) inhibitors in clinical trials
-
Burger JA. Bruton's tyrosine kinase (BTK) inhibitors in clinical trials. Curr Hematol Malig Rep. 2014;9(1):44-49.
-
(2014)
Curr Hematol Malig Rep.
, vol.9
, Issue.1
, pp. 44-49
-
-
Burger, J.A.1
-
67
-
-
84896376113
-
Risk factors for etiology and prognosis of mantle cell lymphoma
-
Wang Y, Ma S. Risk factors for etiology and prognosis of mantle cell lymphoma. Expert Rev Hematol. 2014;7(2):233-243.
-
(2014)
Expert Rev Hematol.
, vol.7
, Issue.2
, pp. 233-243
-
-
Wang, Y.1
Ma, S.2
-
68
-
-
38349104577
-
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
-
Hoster E, Dreyling M, Klapper W, et al; German Low Grade Lymphoma Study Group (GLSG); European Mantle Cell Lymphoma Network. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111(2):558-565.
-
(2008)
Blood
, vol.111
, Issue.2
, pp. 558-565
-
-
Hoster, E.1
Dreyling, M.2
Klapper, W.3
-
69
-
-
84862194194
-
Outcome of deferred initial therapy in mantle-cell lymphoma
-
Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol. 2009;27(8):1209-1213.
-
(2009)
J Clin Oncol.
, vol.27
, Issue.8
, pp. 1209-1213
-
-
Martin, P.1
Chadburn, A.2
Christos, P.3
-
70
-
-
77951453410
-
Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: A European MCL intergroup study
-
Pott C, Hoster E, Delfau-Larue MH, et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood. 2010; 115(16):3215-3223.
-
(2010)
Blood
, vol.115
, Issue.16
, pp. 3215-3223
-
-
Pott, C.1
Hoster, E.2
Delfau-Larue, M.H.3
-
71
-
-
84860392642
-
Utility of positron emission tomography scans in mantle cell lymphoma
-
Hosein PJ, Pastorini VH, Paes FM, et al. Utility of positron emission tomography scans in mantle cell lymphoma. Am J Hematol. 2011;86(10): 841-845.
-
(2011)
Am J Hematol.
, vol.86
, Issue.10
, pp. 841-845
-
-
Hosein, P.J.1
Pastorini, V.H.2
Paes, F.M.3
-
72
-
-
77956181956
-
Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: A retrospective study from the GOELAMS group
-
Bodet-Milin C, Touzeau C, Leux C, et al. Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group. Eur J Nucl Med Mol Imaging. 2010;37(9):1633-1642.
-
(2010)
Eur J Nucl Med Mol Imaging.
, vol.37
, Issue.9
, pp. 1633-1642
-
-
Bodet-Milin, C.1
Touzeau, C.2
Leux, C.3
-
73
-
-
84920582116
-
Is there a role for therapy response assessment with FDG-PET/CT in mantle cell lymphoma?
-
In press
-
Kedmi M, Avivi I, Ribakovsky E, et al. Is there a role for therapy response assessment with FDG-PET/CT in Mantle cell Lymphoma? Leuk Lymphoma. In press.
-
Leuk Lymphoma
-
-
Kedmi, M.1
Avivi, I.2
Ribakovsky, E.3
-
74
-
-
84863334988
-
Posttreatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-hypercvad
-
Mato AR, Svoboda J, Feldman T, et al. Posttreatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD. Cancer. 2012;118(14):3565-3570.
-
(2012)
Cancer
, vol.118
, Issue.14
, pp. 3565-3570
-
-
Mato, A.R.1
Svoboda, J.2
Feldman, T.3
-
75
-
-
49649088421
-
[18F]fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma
-
Gill S, Wolf M, Prince HM, et al. [18F]fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma. Clin Lymphoma Myeloma. 2008;8(3):159-165.
-
(2008)
Clin Lymphoma Myeloma
, vol.8
, Issue.3
, pp. 159-165
-
-
Gill, S.1
Wolf, M.2
Prince, H.M.3
-
76
-
-
20144388941
-
Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: Results of a prospective randomized trial of the European MCL network
-
Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005;105(7):2677-2684.
-
(2005)
Blood
, vol.105
, Issue.7
, pp. 2677-2684
-
-
Dreyling, M.1
Lenz, G.2
Hoster, E.3
-
77
-
-
84872054301
-
CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: A phase 2 study from the groupe d'Etude des lymphomes de l'Adulte
-
Delarue R, Haioun C, Ribrag V, et al; Groupe d'Etude des Lymphomes de l'Adulte (GELA). CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. Blood. 2013; 121(1):48-53.
-
(2013)
Blood
, vol.121
, Issue.1
, pp. 48-53
-
-
Delarue, R.1
Haioun, C.2
Ribrag, V.3
-
78
-
-
74949115388
-
Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: Calgb 59909
-
Damon LE, Johnson JL, Niedzwiecki D, et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol. 2009;27(36):6101-6108.
-
(2009)
J Clin Oncol.
, vol.27
, Issue.36
, pp. 6101-6108
-
-
Damon, L.E.1
Johnson, J.L.2
Niedzwiecki, D.3
-
79
-
-
58549085393
-
High-dose ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients
-
van't Veer MB, de Jong D, MacKenzie M, et al. High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. Br J Haematol. 2009;144(4):524-530.
-
(2009)
Br J Haematol.
, vol.144
, Issue.4
, pp. 524-530
-
-
Van't Veer, M.B.1
De Jong, D.2
MacKenzie, M.3
-
80
-
-
33644810117
-
Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma
-
Bauwens D, Maerevoet M, Michaux L, et al. Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma. Br J Haematol. 2005;131(3):338-340.
-
(2005)
Br J Haematol.
, vol.131
, Issue.3
, pp. 338-340
-
-
Bauwens, D.1
Maerevoet, M.2
Michaux, L.3
-
81
-
-
84895794148
-
Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-hodgkin lymphoma, transformed, or mantle cell lymphoma
-
William BM, Allen MS, Loberiza FR Jr, et al. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma. Biol Blood Marrow Transplant. 2014;20(4): 536-542.
-
(2014)
Biol Blood Marrow Transplant.
, vol.20
, Issue.4
, pp. 536-542
-
-
William, B.M.1
Allen, M.S.2
Loberiza, F.R.3
-
82
-
-
84860109475
-
Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: Results of a phase II trial from the GOELAMS
-
Houot R, Le Gouill S, Ojeda Uribe M, et al; French GOELAMS group. Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS. Ann Oncol. 2012;23(6):1555-1561.
-
(2012)
Ann Oncol.
, vol.23
, Issue.6
, pp. 1555-1561
-
-
Houot, R.1
Le Gouill, S.2
Ojeda Uribe, M.3
-
83
-
-
84862908084
-
A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-hodgkin lymphoma
-
Beaven AW, Shea TC, Moore DT, et al. A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma. Leuk Lymphoma. 2012;53(2):254-258.
-
(2012)
Leuk Lymphoma.
, vol.53
, Issue.2
, pp. 254-258
-
-
Beaven, A.W.1
Shea, T.C.2
Moore, D.T.3
-
84
-
-
79959923820
-
Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma
-
Lamm W, Kaufmann H, Raderer M, et al. Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma. Haematologica. 2011; 96(7):1008-1014.
-
(2011)
Haematologica.
, vol.96
, Issue.7
, pp. 1008-1014
-
-
Lamm, W.1
Kaufmann, H.2
Raderer, M.3
-
85
-
-
79951700533
-
A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the national cancer institute of Canada clinical trials group (IND 172)
-
Kouroukis CT, Fernandez LAV, Crump M, et al. A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172). Leuk Lymphoma. 2011;52(3):394-399.
-
(2011)
Leuk Lymphoma.
, vol.52
, Issue.3
, pp. 394-399
-
-
Kouroukis, C.T.1
Fernandez, L.A.V.2
Crump, M.3
-
86
-
-
77958541490
-
Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and waldenstrom macroglobulinaemia
-
Agathocleous A, Rohatiner A, Rule S, et al. Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenstrom macroglobulinaemia. Br J Haematol. 2010; 151(4):346-353.
-
(2010)
Br J Haematol.
, vol.151
, Issue.4
, pp. 346-353
-
-
Agathocleous, A.1
Rohatiner, A.2
Rule, S.3
-
87
-
-
79958764877
-
Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma
-
Baiocchi RA, Alinari L, Lustberg ME, et al. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma. Cancer. 2011;117(11):2442-2451.
-
(2011)
Cancer.
, vol.117
, Issue.11
, pp. 2442-2451
-
-
Baiocchi, R.A.1
Alinari, L.2
Lustberg, M.E.3
|